Peter Roberts, MD

Articles by Peter Roberts, MD

Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer

ByDavid R. Gandara, MD,Martin Edelman, MD,Primo N. Lara, Jr, MD,Derick H. M. Lau, MD, PhD,Peter Roberts, MD,Bryan R. Leigh, MD

July 2nd 2000

A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung

Latest Updated Articles

Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer
July 2nd 2000

Peter Roberts, MD

Articles by Peter Roberts, MD

Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer

Latest Updated Articles

Trending on CancerNetwork

What Separates a Next-Generation Liver Tumor Board From the Traditional Model?

Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant

BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC

MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance

Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML